この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。
ビジネス · 2014/4/301 分で読めます
Determination of Regulatory Review Period for Purposes of Patent Extension; BRILINTA
ローカル自動翻訳 · 情報源の原言語
概要
The Food and Drug Administration (FDA) has determined the regulatory review period for BRILINTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.
情報源の原言語: Federal Register — Food and Drug Administration原文の発表を開く →